Overall, these results indicate that SMYD3 pharmacological inhibition may represent a novel strategy to enhance the targeting of the HGF/MET pathway for the treatment of GC and warrant further investigation to ascertain its potential in preclinical and, hopefully, clinical settings. Here, SMYD3 is linked to gastric cancer.